1631

Background: Under the label of “bisphenol A (BPA)-free”, a group of bisphenol analogues that are structurally similar to BPA have been developed as the alternatives for industrial applications. Bisphenol analogues are endocrine disrupting compounds (EDCs) and lead to growing concerns upon the potential adverse effects on humans, especially for vulnerable groups, such as pregnant women and infants. Unfortunately, evidence on the association between bisphenol analogues and unexplained recurrent spontaneous abortion (URSA) in pregnant women is still scarce. Objective: Our goal was to explore the associations between the urinary concentrations of bisphenol analogues in pregnant women and the risk of URSA. Methods: A hospital-based case-control study on URSA was carried out in eastern China during 2015 to 2017. The cases were women with unexplained recurrent miscarriage for at least 2 consecutive pregnancies. The controls were women who had normal pregnancy without history of miscarriage. Concentrations of eight bisphenol analogues (A, AF, AP, B, F, P, S, and Z) were measured in the urine samples collected from 775 women (366 URSA cases and 409 controls). A multiple logistic regression was used to evaluate the relationship between urinary bisphenol analogues and URSA. Results: Significantly higher urinary levels of BPA, BPAF, BPAP, BPB, and BPP were found in the URSA women than in the controls (p<0.01). Increased risks of URSA were associated with higher urinary levels of BPAF (adjusted odds ratio (OR)=1.76 for the medium tertile, 95% confidence interval (CI): 1.14, 2.72; adjusted OR=1.87 for the highest tertile, 95% CI: 1.19, 2.93), and a test of the trend for the association was statistically significant (p trend=0.0107). Conclusion: Our findings suggested that prenatal exposure to bisphenol analogues may be associated with URSA risk in a dose-response pattern.